News
09-22-2010, 05:13 AM
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients...
More... (http://mnt.to/f/3K86)
More... (http://mnt.to/f/3K86)